AC Immune SA Рыночная капитализация
Что обозначает Рыночная капитализация в AC Immune SA?
Рыночная капитализация AC Immune SA является $140.95M
Какое определение для Рыночная капитализация?
Рыночная капитализация - это рыночная стоимость в тот момент времени, когда акции, находящиеся в обращении публичной компании, равна цене акций в тот отрезок времени, умноженной на количество акций в обращении .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Рыночная капитализация компаний в Health Care сектор на NASDAQ по сравнению с AC Immune SA
Что делает AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Компании с рыночная капитализация похож на AC Immune SA
- Accel имеет Рыночная капитализация из $140.64M
- PTB имеет Рыночная капитализация из $140.73M
- Sachem Capital Corp имеет Рыночная капитализация из $140.75M
- Probe Metals имеет Рыночная капитализация из $140.86M
- Think Childcare имеет Рыночная капитализация из $140.88M
- Geojit Services имеет Рыночная капитализация из $140.94M
- AC Immune SA имеет Рыночная капитализация из $140.95M
- BGSF Inc имеет Рыночная капитализация из $140.97M
- BG Staffing имеет Рыночная капитализация из $140.97M
- wallstreet:online AG имеет Рыночная капитализация из $141.04M
- Western Asset Municipal High Income Fund Inc имеет Рыночная капитализация из $141.17M
- PYC Therapeutics имеет Рыночная капитализация из $141.21M
- Biosynex SA имеет Рыночная капитализация из $141.23M